Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845 and earlier-stage TIL programs ...

Stanford Medicine researchers discovered a method to induce cancer cell death by manipulating proteins involved in apoptosis.

Go’s “haunted” Scarewash car wash experience is back. Roll through for some fun and frights while supporting local families ...

Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients.

Ladenburg analyst Aydin Huseynov raised the firm’s price target on Marker Therapeutics (MRKR) to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing ...

Lymphoma, a cancer of the immune system, is silently ravaging the health of Black men across America. This insidious disease, ...

The Australian market remained flat over the last week, but it has seen a 22% rise in the past 12 months, with earnings forecasted to grow by 12% annually. For investors willing to explore beyond ...

A patent from Nanjing Mingde New Drug Research Co. Ltd. and Zhangzhou Pientzehuang Pharmaceutical Co. Ltd. details the identification of salts of interleukin-1 receptor-associated kinase 4 (IRAK-4) ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...